Nacho is a 6-year-old child who was diagnosed when he was 3 with the Dent’s disease; a rare untreatable disease which may result in renal failure. Since the diagnosis, his parents have not stop to reverse this situation getting researchers...
Read moreDr. Simó Schwartz, Scientific, appointed president of the European Society for Nanomedicine (ESNAM)
The objectives of ESNAM are to promote nanomedicine research and facilitate the exchange of knowledge among its members (currently, about 800 members). According to Dr. Simó Schwartz “the dissemination of specialized infrastructure in...
Read moreVHIR brings nanomedicine to the Science Festival
The Vall d’Hebron Research Institute (VHIR) participated once again in the Science Festival, which this year has reached its 10th edition. Dr. Víctor Puntes, head of the group of Design and Pharmacodynamics of Nanoparticles, gave a talk...
Read moreVHIR presented the results of three projects of the TV3’s Marathon 2010
On Wednesday 15 June was held the Symposium on acquired spinal cord and brain injuries, in which have been presented the results of the 30 projects funded in the 2010 edition of the TV3 Marathon. Of these projects, three were carried out at the...
Read moreThe Association for Familial Hypomagnesemia donates once again 15000 € for the research of this disease
For the second year in a row, the Association for Information and Research of Familial Hipomagnesemia (Hipofam) has given 15000 euros to the research group on Renal Physiopathology of Vall d’hebron Research Institute (VHIR) to investigate...
Read moreDr. Schwartz Jr participates in a European nanomedicine project for pancreatic cancer
The Drug Delivery and Targeting group from the CIBBIM-Nanomedicine at VHIR, led by Dr. Simó Schwartz Jr., participates in a new European project, called NoCanTher, which aims to develop treatments with nanomedicine for pancreatic ductal...
Read moreDr. Anna Meseguer receives grant from the American Association for Cancer Research
Dr. Anna Meseguer, head of the Kidney Physiopathology group at the Vall d’Hebron Institute of Research (VHIR), has received the 2016 Research Grant for Immunotherapy in Kidney Cancer of the American Association for Cancer Research, endowed with...
Read moreTaking care of your kidneys, and also of the youngest ones’
Renal disease, those that affect the kidneys are not an issue just for adults. Younger children also suffer. A reality that sometimes is hidden and has led to devote this year’s World Kidney Day to preventing diseases that affect children...
Read moreDr Simó Schwartz Jr is appointed editor of the European Journal of Nanomedicine
Dr Simó Schwartz Jr, director of the CIBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VHIR), has been appointed member of the editorial board of the European Journal of Nanomedicine. VHIR’s researcher will review some of the...
Read moreThree VHIR researchers receive three important European grants
Dr. Simó Schwartz Jr, head of the CIBBIM-Nanomedicine Drug Delivery and Targeting group, Dr. Diego Arango, head of the CIBBIM-Nanomedicine Biomedical Research in Digestive Tumors group, and Dr. Mar Hernández-Guillamón, principal investigator of...
Read moreNew methodology to improve the drug response of breast and colon cancer with nanomedicine
Researchers from the Drug Delivery and Targeting group of the CIBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VIHR), have evidenced that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. To be...
Read moreVHIR inaugurates the 2nd edition of the Master’s Degree in Translational Biomedical Research
On September 29th, Vall d’Hebron Institute of Research (VHIR) celebrated the opening day of the 2nd edition of the Official Master’s Degree in Translational Biomedical Research and the closing of the 1st edition, with the diploma award ceremony...
Read more